SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics

SAB Biotherapeutics, Inc., (SABS): $3.88

0.62 (+19.02%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add SABS to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#93 of 393

in industry

SABS Price/Volume Stats

Current price $3.88 52-week high $10.00
Prev. close $3.26 52-week low $2.16
Day low $3.26 Volume 206,800
Day high $3.98 Avg. volume 28,427
50-day MA $2.80 Dividend yield N/A
200-day MA $3.68 Market Cap 35.81M

SABS Stock Price Chart Interactive Chart >


SAB Biotherapeutics, Inc., (SABS) Company Bio


SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.


SABS Latest News Stream


Event/Time News Detail
Loading, please wait...

SABS Latest Social Stream


Loading social stream, please wait...

View Full SABS Social Stream

SABS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!